Sarah Cannon Research Institute
David Adler has extensive work experience in the field of business development, primarily in the healthcare industry. David started their career at GlaxoSmithKline in 1992, where they served as a Sr. Market Development Manager for medical groups until 2009. Following this, they joined McKesson as a Director of Business Development, a role they held from August 2009 to May 2015. David then progressed to the position of Executive Director of Business Development at McKesson's subsidiary, US Oncology Research. In 2021, David joined US ONCOLOGY RESEARCH, LLC as the Vice President of Business Development. Their most recent role is as the Vice President of Business Development at the Sarah Cannon Research Institute, which they assumed in November 2022.
David Adler attended California State University, Northridge from 1982 to 1987. During this time, they obtained a Bachelor of Arts degree in Speech Communications.
This person is not in any offices
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.